HealthEquity (HQY)

Healthcare · Health Information Services
$91.05 -0.55% on the day Market cap $8.1B 52-week range $72.76 to $107.62 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
5% a year for 10 years

At a market value of $8.1B, HealthEquity's free cash flow of $409M (fiscal 2026) would need to grow about 5% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from HealthEquity's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price4.9% a year
Free cash flow, last 9 years32.3% a year
Revenue, same period24.8% a year
Price to free cash flow19.9x

Fundamental grade

B

Five factors scored 1 to 9 from HQY's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation5
Profitability7
Growth5
Financial health6
Cash efficiency9

Key numbers

P/E (trailing)39.4x
P/E (forward)19.5x
Price / free cash flow17.9x
EV / EBITDA17.0x
Price / sales5.97x
Price / book3.86x
Revenue growth+7.6%
Operating margin25.8%
Net margin17.4%
Return on equity11.9%
Dividend yield—
Debt / equity0.64x

Results from SEC filings

Fiscal years, from HealthEquity's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20222023202420252026
Revenue$757M$862M$1000M$1.2B$1.3B
Net income-$44M-$26M$56M$97M$215M
Free cash flow$69M$102M$200M$287M$409M
EPS (diluted)-$0.53-$0.31$0.64$1.09$2.46
Operating margin-3.2%1.1%11.8%13.5%24.6%

Where the revenue comes from

Revenue by products, fiscal 2026.

Custodial$637M48%
Service$485M37%
Interchange$192M15%

Superinvestors who own HQY

From each investor's latest 13F filing (what a 13F shows). 4 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Trimmed $176M0.06%Q2 2026
Hersh Cohen
ClearBridge Investments
Trimmed $117M0.10%Q2 2026
Ron Baron
Baron Capital (BAMCO)
Added $68M0.10%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $2M0.00%Q2 2026

Insider buying

Open-market purchases by HealthEquity's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of HQY in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when HQY trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does HealthEquity's stock price imply?

At a market value of $8.1B, HealthEquity would need its free cash flow to grow about 5% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 32% a year.

Are HealthEquity insiders buying the stock?

No open-market insider purchases of HQY in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own HealthEquity?

4 of the superinvestors Investingly tracks hold HQY in their latest 13F, including Cliff Asness, Hersh Cohen, Ron Baron.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.